Abstract
Deubiquitinating enzymes (DUBs) are responsible for the removal of ubiquitin from substrates, thereby antagonizing ubiquitination and regulating a multitude of biological pathways including cell cycle progression, signal transduction, and transcriptional regulation. Ubiquitin Specific Protease-39 (USP39), a pivotal member of the ubiquitin-specific protease family, is intricately linked to innumerable pathophysiological processes. In this review, we first provide an overview of the specific structural domains and biological functions of USP39, with a particular focus on its role in DNA damage repair and RNA splicing processes. Then, we delineate the function of USP39 in maintaining epithelial morphology, resistance to viral infection, vascular remodeling, and pathological states. Moreover, we particularly focus on the aberrant expression of USP39 in various cancers and its effect on cancer markers, as well as on the regulatory role of USP39 in tumor progression. In conclusion, a comprehensive analysis of the structural domains and functional properties of USP39, a detailed investigation into its interaction mechanisms with diverse substrates, and the accelerated development of related inhibitors will provide a novel theoretical foundation for the treatment of numerous diseases, including tumors. Importantly, targeting USP39 may overcome resistance to checkpoint inhibitors, offering a promising approach to enhance cancer immunotherapy efficacy.
Introduction: The Ubiquitin-Splicing Intersection
In the complex landscape of cellular regulation, two systems are paramount: ubiquitination, which tags proteins for degradation or signaling, and RNA splicing, which edits genetic instructions before protein synthesis. Traditionally studied as separate silos, recent evidence suggests that Ubiquitin Specific Protease-39 (USP39) sits at the critical intersection of these two worlds.
Despite being classified as a deubiquitinating enzyme (DUB), USP39 presents a molecular paradox: its catalytic domain is technically inactive, yet it is essential for cell survival and highly overexpressed in almost every major cancer. This review synthesizes a decade of research to explain how USP39 uses its unique structure to bypass traditional enzymatic rules, driving tumor fitness and facilitating immune evasion.
Methods
This comprehensive review integrates a systematic meta-analysis of 137 primary research papers. The authors synthesized structural biology data (crystal structures of ZnF and UCH domains), biochemical pathway mapping, and clinical data across various malignancies, including hepatocellular carcinoma, lung cancer, and glioma. The analysis utilizes datasets from structural proteomics, cancer cell lines (e.g., SMMC-7721, A549, MCF-7), in vivo xenograft models, and clinical cohorts correlating USP39 levels with patient survival and Gleason scores.
Key Insights and Ideas
USP39 functions as a "pseudo-DUB," likely acting as a scaffold that recruits other active enzymes or through non-canonical interactions rather than direct catalytic activity. It serves as a master splicing mechanic, acting as a core component of the U4/U6·U5 tri-snRNP complex to ensure the correct splicing of mRNA templates for critical cell-cycle regulators like Aurora B and FoxM1.
Crucially, USP39 regulates immune evasion by promoting the correct splicing of CTLA-4 in regulatory T cells (Tregs). This helps tumors maintain an immunosuppressive "shield," preventing T cells from attacking the cancer. Additionally, USP39 has been found to stabilize the E protein of SARS-CoV-2, suggesting it acts as a fundamental stability sensor for both host and pathogen proteins.
Key Results across Malignancies
- Hepatocellular Carcinoma (HCC): USP39 stabilizes ZEB1 and β-catenin, promoting the epithelial-to-mesenchymal transition (EMT) necessary for metastasis.
- Glioma: It facilitates the maturation of TAZ mRNA, a key driver of cancer stemness.
- DNA Repair: USP39 stabilizes CHK2, a kinase essential for the DNA damage response. In cancer cells, this mechanism helps them survive the DNA damage caused by chemotherapy and radiation.
- Cellular Impact: Knockdown of USP39 consistently leads to G2/M phase cell cycle arrest and massive apoptosis in tumor cells, while having significantly less severe effects on healthy tissue.
Discussion and Future Directions
The primary challenge in targeting USP39 is its current "undruggable" status; because its UCH domain is catalytically inactive, traditional active-site inhibitors are ineffective. Future therapeutic strategies include the development of Protein-Protein Interaction (PPI) inhibitors to prevent USP39 from binding to the spliceosome, and PROTACs to flag the entire protein for destruction. Furthermore, combination therapies testing whether USP39 inhibition can re-sensitize tumors to PD-1/PD-L1 checkpoint inhibitors by stripping away the CTLA-4-mediated immune shield represent a promising frontier in oncology.
Summary updated